← Leaderboards
Jennifer A. Woyach
Ohio State University
$6,733,332
Attributed
$14,166,815
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2013–25$2.5M$1.9M$1.3M$625K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,166,815 · 7
By mechanism
R01$13,197,228 · 5
K23$866,160 · 1
P30$103,427 · 1
Top collaborators
- John C Byrd11 shared
- Jin Wang8 shared
- Michael Wang8 shared
- Amy Jo Johnson6 shared
- Rosa Lapalombella5 shared
- Kerry Anne Rogers5 shared
- Kristie A Blum2 shared
Most similar at Ohio State University
Same institution · by research overlap
- Patrick Lee Green$10,720,230
- Amy Jo Johnson$2,112,180
- Michael R Grever$17,739,693
- Kerry Anne Rogers$1,321,382
- Kristie A Blum$3,505,109
Others in their field
Top investigators on “Chronic Lymphocytic Leukemia”
- David Heimbrook · Leidos Biomedical Research, Inc.$30,232,142
- Catherine Ju-Ying Wu · Broad Institute, Inc.$27,924,233
- John C Byrd · University Of Cincinnati$23,347,401
- Gregory H Reaman · National Childhood Cancer Foundation$17,052,970
- Susan L Slager · Mayo Clinic Rochester$15,712,869
- Thomas J. Kipps · University Of California San Diego$14,051,126
Research focus
Chronic Lymphocytic LeukemiaAgammaglobulinaemia Tyrosine KinaseMutationResistanceTargeted TreatmentPharmaceutical PreparationsRefractoryRelapseSignal PathwayReceptor SignalingCellsBaseClinical TrialsMouse ModelPathway InteractionsTyrosine Kinase InhibitorFutureGenomicsResistance MechanismKinase InhibitorDesignReportingSignal TransductionReceptors, Antigen, B-Cell
Grant awards (36)
Targeted Therapies for Lymphoid Malignancies$538,241
R01 · FY2025 · CA · contact PI
Project 03: Leukemia Research (LR)$51,273
P30 · FY2025 · CA · contact PI
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies$610,105
R01 · FY2024 · CA
Targeted Therapies for Lymphoid Malignancies$511,329
R01 · FY2024 · CA · contact PI
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies$68,584
R01 · FY2024 · CA
Project 03: Leukemia Research (LR)$52,154
P30 · FY2024 · CA · contact PI
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies$628,719
R01 · FY2023 · CA
Targeted Therapies for Lymphoid Malignancies$527,476
R01 · FY2023 · CA · contact PI
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies$70,750
R01 · FY2023 · CA
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies$628,719
R01 · FY2022 · CA
Targeted Therapies for Lymphoid Malignancies$527,476
R01 · FY2022 · CA · contact PI
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies$72,195
R01 · FY2022 · CA
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies$641,550
R01 · FY2021 · CA
Targeted Therapies for Lymphoid Malignancies$538,241
R01 · FY2021 · CA · contact PI
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies$671,549
R01 · FY2020 · CA
Dual targeting of XPO1 and BTK in B cell malignancies$496,655
R01 · FY2019 · CA
Improving BTK Directed Therapy for CLL$341,706
R01 · FY2019 · CA · contact PI
Dual targeting of XPO1 and BTK in B cell malignancies$512,016
R01 · FY2018 · CA
Molecular Evaluation of Targeted Therapies in Lymphoid Malignancies$501,285
R01 · FY2018 · CA
Improving BTK Directed Therapy for CLL$352,275
R01 · FY2018 · CA · contact PI
Targeted Therapy for Lymphoid Malignancies$536,708
R01 · FY2017 · CA
Molecular Evaluation of Targeted Therapies in Lymphoid Malignancies$523,187
R01 · FY2017 · CA
Dual targeting of XPO1 and BTK in B cell malignancies$512,016
R01 · FY2017 · CA
Improving BTK Directed Therapy for CLL$352,275
R01 · FY2017 · CA · contact PI
Targeted Therapies and Mechanisms of Resistance in Chronic Lymphocytic Leukemia$173,232
K23 · FY2017 · CA · contact PI
Molecular Evaluation of Targeted Therapies in Lymphoid Malignancies$536,570
R01 · FY2016 · CA
Dual targeting of XPO1 and BTK in B cell malignancies$445,083
R01 · FY2016 · CA
Improving BTK Directed Therapy for CLL$352,275
R01 · FY2016 · CA · contact PI
Targeted Therapies and Mechanisms of Resistance in Chronic Lymphocytic Leukemia$173,232
K23 · FY2016 · CA · contact PI
Molecular Evaluation of Targeted Therapies in Lymphoid Malignancies$527,877
R01 · FY2015 · CA
Improving BTK Directed Therapy for CLL$352,275
R01 · FY2015 · CA · contact PI
Dual targeting of XPO1 and BTK in B cell malignancies$319,550
R01 · FY2015 · CA
Targeted Therapies and Mechanisms of Resistance in Chronic Lymphocytic Leukemia$173,232
K23 · FY2015 · CA · contact PI
Molecular Evaluation of Targeted Therapies in Lymphoid Malignancies$500,541
R01 · FY2014 · CA
Targeted Therapies and Mechanisms of Resistance in Chronic Lymphocytic Leukemia$173,232
K23 · FY2014 · CA · contact PI
Targeted Therapies and Mechanisms of Resistance in Chronic Lymphocytic Leukemia$173,232
K23 · FY2013 · CA · contact PI